The group receiving treatment continues to show positive outcomes with a relapse-free survival rate at a hazard ratio of 0.50 and a p-value of 0.23. In terms of overall survival, the treatment group displayed a hazard ratio of 0.61 with a p-value of 0.52, indicating promising results.